Tongxin Intelligence Medical Completes RMB 100 Million Strategic Financing Led by China Merchants Capital to Build Next-Gen AI-Powered Brain Science Diagnosis and Treatment Platform

Recently, the next-generation AI brain science diagnosis and treatment platform “Tongxin Yilian” announced the completion of a strategic financing round worth hundreds of millions of yuan and officially upgraded its corporate brand to “Sophmind.” This round of financing was led by China Merchants Capital, with Bojia Capital and Bojian Capital participating as co-investors.

The funding will be primarily used to complete the construction of Sophmind’s new-generation AI-driven brain science diagnosis and treatment platform, which integrates R&D, production, and clinical application, as well as to further advance the commercial deployment of its products, thereby fueling subsequent brand upgrades, product development, and market expansion.

China has a large patient population suffering from major brain disorders, creating substantial demand for high-quality neurology medical services. However, the supply side faces uneven distribution of medical resources. Tertiary Grade A hospitals lack auxiliary diagnostic and therapeutic tools with genuine clinical value, making it difficult to extend high-quality medical resources to lower-tier institutions. Meanwhile, primary healthcare facilities encounter significant challenges, including difficulties in disease diagnosis and surgical procedures, as well as a lack of precise treatment plans.

From 2014 to 2022, during its eight years of successful operation, “Sophmind” has consistently adhered to the corporate development orientation of “assisting the nation in balancing medical supply capacity and promoting the expansion of high-quality medical resources.” Leveraging AI-driven brain science technologies as the foundation of its products, Sophmind addresses the demand for intelligent new infrastructure across the entire clinical pathway of major diseases, creating a full-stack, brain science-assisted diagnosis and treatment solution that deeply integrates industry, academia, and research while delivering tangible clinical value.

Through continuous exploration and practice in the fields of smart healthcare and AI technology, Sophmind has established three foundational platforms: the product R&D platform “Sophmind Brain Science,” the product commercialization platform “Sophmind Gewu,” and the product application platform “Sophmind Medical Alliance.” These platforms have laid a solid foundation for the overall realization of the next-generation AI brain science diagnosis and treatment platform, “Sophmind.” Leveraging this infrastructure, Sophmind has successfully implemented a synergistic business loop encompassing “R&D–Product–Application,” ensuring robust operations amidst significant external environmental changes. This achievement further demonstrates the superiority of Sophmind’s forward-looking strategic layout in technology, product development, and commercial translation.

Sophmind Corporate Layout and Strategic Ecosystem Map

Sophmind’s product R&D platform, “Tongxin Brain Science,” addresses key pain points in the AI healthcare industry—such as the lack of interpretability in traditional deep learning algorithms, poor model generalizability, and limited clinical application—by establishing a deep technical collaboration with Professor Cui Peng’s team from the Department of Computer Science and Technology at Tsinghua University. Together, they have launched China’s first innovative algorithm that integrates causal inference, deep learning, and hemodynamics. This algorithm effectively identifies statistical confounders, pinpoints disease-associated indicators with true causal relationships, and achieves stable predictions across different data distributions. By leveraging a unified algorithmic platform to address various neurological disorders, it has significantly enhanced both algorithmic robustness and interpretability.

Supported by a distinguished technical team and a robust foundation in innovative algorithms, Sophmind has established the AI product commercialization platform “Tongxin Gewu,” dedicated to addressing critical bottlenecks in core technologies and facilitating resource accumulation. The company has jointly applied for key medical research projects with top-tier Grade A tertiary hospitals, including Beijing Tiantan Hospital and Peking Union Medical College Hospital, and has successfully developed over ten intelligent brain science analysis products, such as AI-powered aneurysm analysis and whole-brain quantitative analysis. Multiple of these products have obtained certification from the National Medical Products Administration (NMPA).

Building on the continuous refinement of its technology and products, Sophmind independently developed “Tongxin Medical Alliance” (the predecessor of Sophmind), a product application platform that enables seamless two-way connectivity between its online internet hospital and offline medical institutions and imaging centers. The company has established collaborations with numerous hospital clients, precisely identifying clinical physicians’ needs and equipping them with corresponding AI-assisted solutions. While ensuring effective product adoption, Sophmind has accumulated substantial resources and user feedback, which in turn fuel further technological advancement and product iteration.

Since then, Sophmind has established a comprehensive portfolio of neurology products covering multiple diseases, scenarios, and care cycles. The next-generation AI-powered neuroscience diagnosis and treatment platform has been officially launched, marking the initial completion of its strategic business ecosystem layout characterized by “three platforms, dual-end drive, mutual support, and revenue assurance.”

To date, Sophmind’s products and services have covered 26 provinces across China, serving more than 500 imaging centers and medical institutions. It has cumulatively served over 330,000 patients and managed more than 39 million medical records. By collaborating with numerous top-tier experts in the fields of brain science and mental disorders, Sophmind has continuously commercialized 42 patented intellectual property rights and established a pipeline of 20 neurological disease products. In 2021, amidst the pandemic, Sophmind still achieved a threefold increase in revenue, demonstrating strong growth potential and sustainable development capabilities.

Liu Weiqi, Founder and CEO of Sophmind, stated: “Sophmind is built upon Peter Thiel’s theory of ‘complexity collaboration,’ aligning and integrating the needs and resources of all parties involved in AI technology R&D, product application commercialization, and end-user implementation. This approach has established a business model that is difficult to replicate, laying the foundation for Sophmind’s competitive advantage in the field of AI-driven diagnosis and treatment technologies for brain science.”

Hu Xian, an expert committee member for the healthcare sector at China Merchants Capital, stated: “The application of artificial intelligence in the healthcare industry has entered its second half. Only AI projects that can genuinely enhance diagnostic and therapeutic standards, reduce clinical risks, and deliver clear, tangible benefits to patients in serious medical settings align with the logic of medical technological advancement and healthcare investment. We highly appreciate and recognize the forward-looking strategic vision and layout planning of the Sophmind team. Their innovative ‘causal inference’ AI algorithms in brain science, along with their newly established self-circulating next-generation AI platform for brain science diagnosis and treatment, demonstrate strong technological leadership and effectively bridge the gap between technology and rigorous clinical needs. We are honored to have successfully partnered with Sophmind and look forward to working together with the company to help balance the nation’s healthcare supply capacity, expand access to high-quality medical resources, and realize the new infrastructure for smart healthcare in China.”

Tian Bo, founder of Bojia Capital, stated: “Sophmind leverages its advanced algorithms and technological capabilities to develop AI-driven diagnostic and auxiliary diagnostic products for major neurological conditions, such as brain tumors. By addressing the genuine market demand for scientifically enhancing the diagnosis and treatment of critical illnesses, it resolves the industry pain point of insufficient diagnostic and therapeutic capabilities at primary healthcare institutions, capitalizing on the opportunities presented by the new infrastructure development in the healthcare sector. Bojia Capital is optimistic about Sophmind’s ability to develop more targeted algorithms based on modern medical theories, going beyond traditional machine learning or deep learning. At a time when neurological medical resources in China are overly concentrated and the diagnostic capabilities of primary healthcare facilities urgently need improvement, Sophmind holds significant social and commercial value.”

Zou Mingxi, Executive Director of Bojian Capital, stated, “We are delighted to see that Sophmind has demonstrated a clearer strategic layout and development plan in this brand upgrade. By integrating and complementing multiple business platforms, they have built a new-generation AI brain science diagnosis and treatment platform aimed at balancing the efficiency of innovative technology application with high-quality medical resources. This serves the high-quality development of healthcare institutions and patients, thereby contributing to the national goal of balanced medical supply capacity. This aligns closely with Bojian Capital’s investment philosophy. We look forward to working together with Sophmind to continue contributing to further balancing supply and demand and improving efficiency in medical services.”

It is reported that Sophmind will complete and launch a series of products covering the entire clinical application process of AI in neuroscience healthcare in 2022, accelerating the deployment of its AI medical products and technologies to truly achieve full-process coverage for single diseases. Meanwhile, Sophmind will initiate a new round of financing in the near future.

China Merchants Capital was established in 2012 as a key subsidiary of China Merchants Group. In 2019, it advanced mixed-ownership reform by introducing strategic investors and is now a joint venture between China Merchants Group and GLP. Currently, China Merchants Capital manages over 50 RMB and foreign currency funds, including national-level and market-oriented fund-of-funds, venture capital funds, and other types, with total assets under management reaching RMB 300 billion, making it a leading asset management institution in China.

Bojia Capital is a private equity investment management firm founded by professionals specializing in equity financing and investment within domestic and international capital markets. Focusing on sectors such as new consumption, the internet, advanced manufacturing, new materials, and fintech, Bojia Capital leverages its team’s extensive financial industry experience, multinational corporate management expertise, and in-depth industry research and project financing capabilities to provide boutique and diversified investment and financing services to high-growth emerging enterprises. Committed to becoming a renowned boutique investment bank in the industry, Bojia Capital acts as a value investor that seizes timely opportunities, growing alongside outstanding companies while achieving substantial investment returns.

Foresight Capital is a leading private equity investment firm in China, committed to helping entrepreneurs build successful businesses. Over the past decade, it has generated substantial returns for its investors. Foresight Capital focuses on investment opportunities in information technology and healthcare, with its investment scope primarily covering growth-stage, mature-stage, and mergers and acquisitions/restructuring phases.